reports
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SHBI SHORE BANCSHARES INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NSP INSPERITY INC.
NPO ENPRO INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
LLY ELI LILLY AND COMPANY
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EIG EMPLOYERS HOLDINGS INC.
CNOB CONNECTONE BANCORP INC.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CHD CHURCH & DWIGHT CO. INC.
CDXS CODEXIS
ARW ARROW ELECTRONICS INC.
AMH AMERICAN HOMES 4 RENT CLASS A
CIVB CIVISTA BANCSHARES
OLN OLIN CORPORATION
ASUR ASURE SOFTWARE INC
BRO BROWN & BROWN INC.
CYRX CRYOPORT INC.
FTV FORTIVE CORP.
CLAR CLARUS CORPORATION
A2H9KJ NEO PERFORMANCE MATERIAL
OSPN ONESPAN
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
XRX XEROX HOLDINGS CORPORATION
PINE ALPINE INCOME PROPERTY TRUST
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
LRMR LARIMAR THERAPEUTICS INC
THRY THRYV HOLDINGS
DLHC DALEIGH HOLDINGS CORP
INTA INTAPP INC
PTLO PORTILLOS INC
BRBR BELLRING BRANDS INC
AUB ATLANTIC UNION BANKSHARES CORP
AURX NUO THERAPEUTICS
OI INC.
SIRI OWENS ILLINOIS INC.
XELB SIRIUS XM HLDGS INC NEW
MUSA XCEL BRANDS INC.
LNW METALS USA HOLDINGS CORP.
LIGHT & WONDER INC.
- Jonathan Moreland
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NPO ENPRO INDUSTRIES INC.
LLY ELI LILLY AND COMPANY
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
BRO BROWN & BROWN INC.
CRSP CRISPR THERAPEUTICS AG
OSPN ONESPAN
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
PINE ALPINE INCOME PROPERTY TRUST
PTLO PORTILLOS INC
AUB ATLANTIC UNION BANKSHARES CORP
LNW LIGHT & WONDER INC.
Opko Health Inc: 1 director
A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
HCI Group Reports Second Quarter 2025 Results
HCI Group Reports Second Quarter 2025 Results Second Quarter Pre-Tax Income of $94.4 million and Diluted EPS of $5.18Book Value Per Share Increased to $58.55Gross Loss Ratio of 21.3% TAMPA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), reported pre-tax income of $94.4 million and net income of $70.3 million for the second quarter of 2025. Net income after noncontrolling interests was $66.2 million compared with $54.1 million in the second quarter of 2024. Diluted earnings per share were $5.18 in the second quarter of 2025, compared with $4.24 in the second quart...
OPKO Health Reports Second Quarter 2025 Business Highlights and Financ...
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
OPKO Health to Report Second Quarter 2025 Financial Results on July 31 MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on July 31 beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-re...
Western Asset High Income Opportunity Fund Inc: 1 director
A director at Western Asset High Income Opportunity Fund Inc maiden bought 10,000 shares at 4.018USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
HCI Group Sets Second Quarter 2025 Earnings Call for Thursday, August ...
HCI Group Sets Second Quarter 2025 Earnings Call for Thursday, August 7, 2025, at 4:45 p.m. ET TAMPA, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) will hold a conference call on Thursday, August 7, 2025, at 4:45 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2025. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer period. Interested parties can listen to the live presentation by dialing the listen-only number below or by clicking t...
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Ta...
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. A...
HCI Group Declares Quarterly Cash Dividend
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- The board of directors of (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid September 19, 2025 to shareholders of record at the close of business August 15, 2025. About HCI Group, Inc.HCI Group is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real estate. The second uni...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obe...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics ...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Gluc...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisc...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Adv...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), to...
HCI Group Announces Completion of its 2025 – 2026 Catastrophe Reinsura...
HCI Group Announces Completion of its 2025 – 2026 Catastrophe Reinsurance Programs TAMPA, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) has successfully completed its catastrophe reinsurance programs for the 2025-2026 treaty year, which runs from June 1, 2025 through May 31, 2026. “We are grateful for the strong support from our global reinsurance partners, whose continued confidence in HCI underscores the quality of our underwriting and our disciplined approach to risk,” said Paresh Patel, HCI’s chairman and chief executive officer. “We believe our reinsurance programs are pruden...
OPKO Health to Participate in Two Upcoming Investor Conferences
OPKO Health to Participate in Two Upcoming Investor Conferences MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meet...
HCI Group Reports First Quarter 2025 Results
HCI Group Reports First Quarter 2025 Results First Quarter Diluted EPS of $5.35First Quarter Pre-Tax Income of $100.3 millionExzeo Ready to be Standalone Company TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI) reported pre-tax income of $100.3 million and net income of $74.2 million for the first quarter of 2025. Net income after noncontrolling interests was $69.7 million compared with $47.6 million in the first quarter of 2024. Diluted earnings per share were $5.35 in the first quarter of 2025, compared with $3.81 diluted earnings per share, in the first...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XPL SOLITARIO ZINC
RGP RESOURCES CONNECTION INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
LPG DORIAN LPG
WHF WHITEFIELD
AMTX AEMETIS
GCBC GREENE COUNTY BANCORP INC.
JFR NUVEEN FLOATING RATE INCOME FUND
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
DOMO DOMO INCORPORATED
BCDA BIOCARDIA
PCB PACIFIC CITY FINANCIAL CORP
ASAN ASANA
PCVX VAXCYTE
WOOF PETCO HEALTH AND WELLNESS
NUVB NUVATION BIO INC (A)
CTGO CONTANGO ORE INC.
SMMT SUMMIT THERAPEUTICS INC
HUMA HUMACYTE INC
TCBX THIRD COAST BANCSHARES INC
PEPG PEPGEN INC
GLSI GREENWICH LIFESCIENCES INC
JMSB JOHN MARSHALL BANCORP INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMTC NEUROONE MEDICAL TECHNOLOGIES CORP
SSII SS INNOVATIONS INTERNATIONAL INC
CATX PERSPECTIVE THERAPEUTICS
DMA INC.
SUNS DESTRA MULTI ALTERNATIVE FUND
NUTX SUNRISE REALTY TRUST
AFCG NUTEX HEALTH INC
FTLF AFC GAMMA
INC.
FITLIFE BRANDS INC.
OPKO Health Reports First Quarter 2025 Business Highlights and Financi...
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory te...
HCI Group Declares Quarterly Cash Dividend
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- The board of directors of (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid June 20, 2025 to shareholders of record at the close of business May 16, 2025. About HCI Group, Inc.HCI Group is a holding company with two distinct operating units. The first unit includes four top-performing insurance companies, a captive reinsurance company, and operations in claims management and real estate. The second unit, call...
HCI Group Sets First Quarter 2025 Earnings Call for Thursday, May 8, 2...
HCI Group Sets First Quarter 2025 Earnings Call for Thursday, May 8, 2025, at 4:45 p.m. ET TAMPA, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- (NYSE: HCI) will hold a conference call on Thursday, May 8, 2025, at 4:45 p.m. Eastern time to discuss results for the first quarter ended March 31, 2025. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer period. Interested parties can listen to the live presentation by dialing the listen-only number below or by clicking the web...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.